CoChat
Sign Up
Cited by 86Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCutaneous lymphoproliferative disorders research

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

Open access
Shadman, Mazyar, Li, Hongli, Rimsza, Lisa, Leonard, John P., Kaminski, Mark S., Braziel, Rita M., Spier, Catherine M., Gopal, Ajay K., Maloney, David G., Cheson, Bruce D., Dakhil, Shaker, LeBlanc, Michael, Smith, Sonali M., Fisher, Richard I., Friedberg, Jonathan W., Press, Oliver W.·2018·Journal of Clinical Oncology
DOI 10.1200/jco.2017.74.5083PMC PMC6553811
Open this paper in CoChat — free account

Abstract

Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133-tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-term outcome of patients provides a benchmark for novel treatment regimens for FL. Patients and Methods Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, III, or IV) of any pathologic grade (1, 2, or 3) were eligible. Results After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49% and 78% among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56% v 42%; P = .01), but 10-year overall survival was not different between the two arms (75% v 81%; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% v 3.2%; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4% v 0.9%; P = .02). Conclusion Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-term follow-up of alternative approaches demonstrates superiority.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.2017.74.5083

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In SWOG S0016, the estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% vs 3.2%; P=0.16).

    “The estimated 10-y cumulative incidences of death resulting from second malignancies were not different (7.1% vs. 3.2%; P 5 0.16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOPRIT arm than in the R-CHOP arm (4% vs. 0.9%; P 5 0.02 ( 101 )).”

    From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [101]

  • In SWOG S0016, there was no significant difference between the CHOP-RIT and R-CHOP arms in incidence of second malignancies (15.1% vs 16.1%; P=0.81).

    “There was no signi fi cant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% vs. 16.1%; P 5 0.81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% vs. 1.8%; P 5 0.058).”

    From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [101]

  • In SWOG S0016, the cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm than in the R-CHOP arm (4% vs 0.9%; P=0.02).

    “The estimated 10-y cumulative incidences of death resulting from second malignancies were not different (7.1% vs. 3.2%; P 5 0.16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOPRIT arm than in the R-CHOP arm (4% vs. 0.9%; P 5 0.02 ( 101 )).”

    From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [101]

  • In SWOG S0016, patients in the CHOP-RIT arm had significantly better 10-year progression-free survival than patients in the R-CHOP arm (56% vs 42%; P=0.01).

    “Patients in the CHOP-RIT arm had signi fi cantly better 10-y progression-free survival than patients in the R-CHOP arm (56% vs. 42%; P 5 0.01), but 10-y overall survival was not different between the 2 arms (75% vs. 81%; P 5 0.13).”

    From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [101]

  • In SWOG S0016, there was no significant difference between the CHOP-RIT and R-CHOP arms in incidence of myelodysplastic syndrome or acute myeloid leukemia (4.9% vs 1.8%; P=0.058).

    “There was no signi fi cant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% vs. 16.1%; P 5 0.81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% vs. 1.8%; P 5 0.058).”

    From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [101]

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Shadman, M., Li, H., Rimsza, L., Leonard, J. P., Kaminski, M. S., Braziel, R. M., Spier, C. M., Gopal, A. K., Maloney, D. G., Cheson, B. D., Dakhil, S., LeBlanc, M., Smith, S. M., Fisher, R. I., Friedberg, J. W., & Press, O. W.
Affiliations
University of Arizona (US)
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2018-03-01
Volume
36
Issue
7
Pages
697-703
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2017.74.5083
PMC
PMC6553811
OpenAlex
W2784962174
Cited by
86
References
27
Citations by year
2026: 5 · 2025: 8 · 2024: 7 · 2023: 9 · 2022: 11 · 2021: 12 · 2020: 10 · 2019: 9 · 2018: 13
FWCI
8.37
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UA Campus Repository (The University of Arizona) (acceptedVersion)
Funders
  • Gilead Sciences (CA180821, CA180888)
  • Celgene
  • TG Therapeutics
  • Genentech
  • Pharmacyclics
  • National Cancer Institute (UG1CA189822, UG1CA189953, UG1CA189808, UG1CA189952, U10CA180828, UG1CA189957, U10CA180846, UG1CA189853, U10CA180835, UG1CA189848, U10CA180888, U10CA180819, UG1CA189804, U10CA180801, UG1CA189860, U10CA180818, UG1CA189997, UG1CA189858, UG1CA189809, UG1CA189972, U10CA180821, UG1CA189872)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
Keywords
follicular lymphoma, R-CHOP, iodine-131 tositumomab, radioimmunotherapy, treatment-naive patients, progression-free survival, overall survival, secondary malignancies, myelodysplastic syndrome, acute myeloid leukemia, long-term follow-up, chemoimmunotherapy
MeSH terms
Rituximab, Antineoplastic Combined Chemotherapy Protocols, Cause of Death, Cyclophosphamide, Doxorubicin, Female, Follow-Up Studies, Humans, Lymphoma, Follicular, Male, Middle Aged, Prednisone, Prognosis, Vincristine, Radioimmunotherapy, Neoplasms, Second Primary, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review